OmicScouts GmbH, an IZB-based leader in mass spectrometry-based proteomics, has been acquired by Momentum Biotechnologies. Momentum, a contract research organization specializing in mass spectrometry-based drug discovery, announced today that OmicScouts will now operate as OmicScouts, a Momentum Biotechnologies Company. With this transaction, OmicScouts gains the support and resources of Momentum, allowing it to further expand its impact in mass spectrometry-based proteomics. The collaboration enhances OmicScouts’ ability to offer a broader range of well-validated proteomic assays, helping clients seamlessly transition from high-throughput screening to cell-based assays and accelerate target and biomarker discovery. This combination strengthens the value chain by offering end-to-end solutions that integrate both small molecule screening and proteomics expertise. Additionally, joining forces with Momentum provides OmicScouts with a stronger global reach, enabling deeper engagement with biopharmaceutical innovators while maintaining its commitment to scientific excellence.

“Our clients have long requested our help triaging and further interrogating the hits we uncover through high-throughput screens. With the addition of OmicScouts’ leading chemoproteomic capabilities, we are now able to take projects beyond hit identification to interrogate target engagement, selectivity/specificity, and global drug response, effectively closing the existing gap between biochemical hit triage and downstream cell-based and preclinical assays,” says Can Ozbal, Ph.D., founder and CEO of Momentum Biotechnologies. “We are excited about this opportunity to expand our service capabilities while maintaining our mutual commitments to customer satisfaction, scientific rigor, and ongoing technological innovation.”

OmicScouts’ co-founder and CEO Hannes Hahne, Ph.D. will transition into a new role as President and member of Momentum’s global executive leadership team following the integration: “OmicScouts was founded from our desire to give researchers the tools and talent needed for proteomics-based drug discovery. The Momentum team shared a similar vision to make high-throughput mass spectrometry accessible to drug developers, and I am excited to combine forces towards an even bigger vision of providing the ultimate drug discovery cascade with screening through proteomics.”

Both companies uphold a strong scientific foundation and a deep commitment to customer-centric innovation, making this acquisition a natural cultural and strategic fit. “OmicScouts and Momentum are both distinguished by technical excellence and strong, trust-based client relationships. This combination allows us to integrate OmicScouts’ proteomics expertise with our screening technologies and ultimately accelerate the drug design process for clients,” says Peter Batesko, Lead Director of Momentum and Managing Partner of Care Equity.

Two of OmicScouts’ co-founders and scientific advisers, Mathias Wilhelm, Ph.D., and Bernhard Kuster, Ph.D., will join Momentum’s Scientific Advisory Board, bringing their expertise to support the combined team. “I am excited to serve as an advisor for this exceptional group as they continue to develop and expand their service offerings and offer unique insights to clients through rich, high-quality mass spectrometry data,” says Wilhelm. Kuster adds, “My lab continued to work closely with Hannes and OmicScouts to translate cutting-edge proteomics methods from academia into tangible therapeutic innovations. The impact of proteomics on drug discovery is only starting to gain recognition, and we are excited to accelerate these advancements.”

About Momentum Biotechnologies
Momentum Biotechnologies, founded in 2014, is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. Thanks to their proven workflows, state-of-the-art facilities, and extensive mass spectrometry experience, Momentum is uniquely positioned to deliver rapid, reliable answers to a wide range of pressing research questions. For more information, please visit www.momentum.bio.

About OmicScouts
OmicScouts, founded in 2014, is a proteomics company focused on supporting drug and biomarker discovery through unique expertise and innovative technologies. By providing and developing system-wide assays to monitor protein activity and function in a physiological context, OmicScouts enables the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action, and drug response biomarkers. OmicScouts supports a wide variety of drug and biomarker discovery projects with end-to-end solutions tailored to project-specific needs, and the team has a strong track record of successful collaborations with top pharmaceutical and biotechnology companies. To learn more, visit www.omicscouts.com.